Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Antigenics Raising $31.6M Via Stock Sale To Single Investor

Sep. 22, 2003

By Aaron Lorenzo and Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Tercica, Armed With Genentech Technology, Seeks $86.25M IPO

Sep. 15, 2003

By Brady Huggett

View All Articles by Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...